Optimization of radiation dose and time and identification of potential biomarkers can further enhance the effectiveness of this unique combination, and a better understanding of how the cGAS/STING pathway mediates anti-tumor effects will contribute to the use of STING agonists in cancer therapy and design better treatment regimens. This evidence concerns the gene CGAS and neoplasm.